Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy

This study assessed baricitinib's efficacy and safety in 5 patients with severe alopecia areata (AA) and coexisting psoriasis and/or psoriatic arthritis (PsA) over 52 weeks. Baricitinib was effective for AA, with 1 patient achieving complete remission and 2 others showing significant improvement. Psoriasis remained stable, with a mean PASI score reduction from 1.4 to 0.5. However, baricitinib was less effective for PsA, as 1 patient experienced worsening joint symptoms and discontinued treatment. The study suggests baricitinib may benefit AA and psoriasis but may not be optimal for PsA, indicating a need for further research. The small sample size limits the generalizability of the results.